Teva Pharmaceutical Industries (TEVA) Financials

$35.91 +0.18 (+0.50%)

Closing price 03:59 PM Eastern

Extended Trading

$35.96 +0.05 (+0.13%)

As of 04:55 PM Eastern

Annual Income Statements for Teva Pharmaceutical Industries

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	1,573	68	-16,525	-2,399	-999	-3,990	417	-2,446	-559	-1,639	1,410
Consolidated Net Income / (Loss)	1,597	311	-16,449	-2,472	-1,000	-4,099	456	-2,499	-615	-1,959	1,418
Net Income / (Loss) Continuing Operations	1,597	311	-16,449	-2,472	-1,000	-4,100	456	-2,499	-615	-1,959	1,418
Total Pre-Tax Income	2,352	824	-18,379	-2,596	-1,265	-4,406	658	-3,163	-624	-1,284	1,223
Total Operating Income	3,352	2,154	-17,484	-1,637	-443	-3,572	1,716	-2,197	433	-303	2,157
Total Gross Profit	11,356	11,653	10,615	8,296	7,537	7,726	7,594	6,973	7,645	8,064	8,938
Total Revenue	19,652	21,903	21,853	18,271	16,887	16,659	15,878	14,925	15,846	16,544	17,258
Operating Revenue	19,652	21,903	21,853	18,271	16,887	16,659	15,878	14,925	15,846	16,544	17,258
Total Cost of Revenue	8,296	10,250	11,237	9,975	9,351	8,933	8,284	7,952	8,200	8,481	8,320
Operating Cost of Revenue	8,296	10,250	11,237	9,975	9,351	8,933	8,284	7,952	8,200	8,481	8,320
Total Operating Expenses	8,004	9,499	28,099	9,933	7,980	11,297	5,879	9,170	7,213	8,366	6,780
Selling, General & Admin Expense	1,360	1,390	1,451	1,298	1,192	1,173	1,099	1,180	1,162	1,161	1,287
Marketing Expense	3,478	3,583	3,395	2,916	2,614	2,498	2,429	2,265	2,336	2,541	2,686
Research & Development Expense	1,525	2,077	1,778	1,213	1,010	997	967	838	953	998	1,013
Other Operating Expenses / (Income)	-166	-769	-1,199	-291	-76	-40	-98	-107	-49	-14	18
Impairment Charge	1,176	2,319	20,338	5,018	1,639	6,130	424	2,400	1,050	1,531	259
Restructuring Charge	-	-	1,836	987	423	479	341	512	718	1,388	1,050
Other Special Charges / (Income)	631	899	500	-1,208	1,178	60	717	2,082	1,043	761	467
Total Other Income / (Expense), net	-1,000	-1,330	-895	-959	-822	-834	-1,058	-966	-1,057	-981	-934
Other Income / (Expense), net	-1,000	-1,330	-895	-959	-822	-834	-1,058	-966	-1,057	-981	-934
Income Tax Expense	634	521	-1,933	-195	-278	-168	211	-643	-7.00	676	-180
Other Gains / (Losses), net	-121	8.00	-3.00	-71	-13	138	9.00	21	2.00	1.00	15
Net Income / (Loss) Attributable to Noncontrolling Interest	9.00	-18	-184	-322	-2.00	-109	39	-53	-56	-320	7.00
Basic Earnings per Share	$1.84	$0.07	($16.26)	($2.35)	($0.91)	($3.64)	$0.38	($2.20)	($0.50)	($1.45)	$1.23
Weighted Average Basic Shares Outstanding	855M	955M	1.02B	1.02B	1.09B	1.10B	1.10B	1.11B	1.12B	1.13B	1.15B
Diluted Earnings per Share	$1.82	$0.07	($16.26)	($2.35)	($0.91)	($3.64)	$0.38	($2.20)	($0.50)	($1.45)	$1.21
Weighted Average Diluted Shares Outstanding	1.02B	961M	1.02B	1.02B	1.09B	1.10B	1.11B	1.11B	1.12B	1.13B	1.16B
Weighted Average Basic & Diluted Shares Outstanding	1.02B	1.12B	1.02B	1.02B	1.09B	1.10B	1.10B	1.11B	1.12B	1.13B	1.15B

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	69	464	-139	-846	-437	-217	214	282	433	481	369
Consolidated Net Income / (Loss)	77	467	-419	-874	-390	-276	220	283	434	481	369
Net Income / (Loss) Continuing Operations	77	467	-419	-874	-390	-276	220	282	434	482	369
Total Pre-Tax Income	65	506	-467	-246	-324	-247	294	203	646	80	437
Total Operating Income	345	755	-218	-5.00	-51	-29	519	455	882	301	652
Total Gross Profit	1,851	2,416	1,771	2,024	2,148	2,121	1,877	2,102	2,304	2,655	1,972
Total Revenue	3,850	4,457	3,819	4,164	4,332	4,229	3,891	4,176	4,480	4,711	3,982
Operating Revenue	3,850	4,457	3,819	4,164	4,332	4,229	3,891	4,176	4,480	4,711	3,982
Total Cost of Revenue	1,999	2,040	2,048	2,140	2,183	2,110	2,014	2,074	2,176	2,056	2,011
Operating Cost of Revenue	1,999	2,040	2,048	2,140	2,183	2,110	2,014	2,074	2,176	2,056	2,011
Total Operating Expenses	1,506	1,662	1,988	2,030	2,198	2,150	1,356	1,647	1,422	2,355	1,319
Selling, General & Admin Expense	268	291	278	283	298	302	297	305	317	368	304
Marketing Expense	576	611	608	656	626	651	622	654	656	754	696
Research & Development Expense	253	226	242	269	240	247	247	244	256	266	222
Other Operating Expenses / (Income)	-9.00	-5.00	1.00	-2.00	-21	8.00	5.00	4.00	7.00	2.00	-9.00
Impairment Charge	104	5.00	80	461	628	362	121	42	64	32	8.00
Restructuring Charge	-	-	673	280	-23	458	-22	232	62	778	26
Other Special Charges / (Income)	314	34	106	83	450	122	86	166	60	155	72
Total Other Income / (Expense), net	-280	-249	-250	-241	-272	-218	-225	-252	-237	-220	-216
Other Income / (Expense), net	-280	-249	-250	-241	-272	-218	-225	-252	-237	-220	-216
Income Tax Expense	-12	40	-52	630	69	29	74	-78	214	-390	67
Other Gains / (Losses), net	0.00	1.00	-4.00	2.00	3.00	-	0.00	1.00	2.00	12	-1.00
Net Income / (Loss) Attributable to Noncontrolling Interest	8.00	4.00	-280	-29	47	-58	6.00	0.00	1.00	-	0.00
Basic Earnings per Share	$0.06	$0.42	($0.12)	($0.75)	($0.39)	($0.19)	$0.19	$0.25	$0.38	$0.41	$0.32
Weighted Average Basic Shares Outstanding	1.12B	1.12B	1.12B	1.13B	1.13B	1.13B	1.14B	1.15B	1.15B	1.15B	1.16B
Diluted Earnings per Share	$0.06	$0.42	($0.12)	($0.75)	($0.39)	($0.19)	$0.18	$0.24	$0.37	$0.42	$0.31
Weighted Average Diluted Shares Outstanding	1.14B	1.12B	1.12B	1.13B	1.13B	1.13B	1.16B	1.16B	1.16B	1.16B	1.18B
Weighted Average Basic & Diluted Shares Outstanding	1.12B	1.12B	1.13B	1.13B	1.13B	1.13B	1.15B	1.15B	1.15B	1.15B	1.16B

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	4,720	-5,958	-25	4,607	1,073	202	1,850	636	393	74	256
Net Cash From Operating Activities	5,542	3,890	2,225	2,446	748	1,216	798	1,590	1,368	1,247	1,649
Net Cash From Continuing Operating Activities	5,542	3,890	2,225	6,092	1,644	1,216	2,499	1,590	1,368	1,247	1,649
Net Income / (Loss) Continuing Operations	1,597	311	-16,449	-2,472	-1,000	-4,099	456	-2,499	-615	-1,959	1,418
Consolidated Net Income / (Loss)	1,597	311	-16,449	-2,472	-1,000	-4,099	456	-2,499	-615	-1,959	1,418
Depreciation Expense	1,308	1,524	2,112	1,842	1,722	1,557	1,330	1,308	1,153	1,059	1,002
Non-Cash Adjustments To Reconcile Net Income	1,287	2,170	20,525	3,960	2,273	6,542	1,391	2,581	1,158	2,656	1,185
Changes in Operating Assets and Liabilities, net	1,350	-115	-3,963	-884	-1,351	-2,784	-678	200	-328	-509	-1,956
Net Cash From Investing Activities	-5,565	-34,405	3,446	1,866	1,355	863	1,523	656	968	792	737
Net Cash From Continuing Investing Activities	-5,565	-34,405	3,446	1,866	1,355	863	1,523	656	968	792	737
Purchase of Property, Plant & Equipment	-772	-901	-874	-651	-525	-578	-562	-548	-526	-498	-501
Acquisitions	-3,309	-36,148	-	-	-	0.00	0.00	-7.00	0.00	-15	0.00
Purchase of Investments	-2,003	-481	-200	-119	-8.00	-55	-47	-1.00	-46	-71	-57
Divestitures	-	-	43	-	343	67	311	68	68	43	34
Sale and/or Maturity of Investments	524	2,002	3,477	890	2.00	12	172	4.00	0.00	40	42
Other Investing Activities, net	-5.00	1,123	1,000	1,746	1,543	1,417	1,649	1,140	1,472	1,293	1,219
Net Cash From Financing Activities	4,805	25,217	-5,750	-3,351	-1,926	-1,885	-2,172	-1,487	-1,913	-1,791	-2,151
Net Cash From Continuing Financing Activities	4,805	25,217	-5,750	-3,351	-1,926	-1,885	-2,172	-1,487	-1,913	-1,791	-2,151
Repayment of Debt	-2,699	-1,168	-5,057	-7,763	-2,374	-2,435	-2,381	-1,487	-5,064	-1,649	-4,071
Payment of Dividends	-1,155	-1,558	-1,199	-22	-52	-	-	0.00	0.00	-78	-340
Issuance of Debt	2,128	27,250	506	4,434	500	550	700	0.00	3,151	0.00	2,298
Other Financing Activities, net	388	35	-	-	0.00	-	-491	0.00	0.00	-64	-38
Other Net Changes in Cash	-	-660	54	-	-	8.00	-	-123	-30	-174	21
Cash Interest Paid	243	290	795	815	840	846	913	948	1,078	1,004	950

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-420	977	-236	-733	1,061	-18	-1,603	464	42	1,353	185
Net Cash From Operating Activities	5.00	1,184	-124	103	693	575	-105	227	369	1,158	-40
Net Cash From Continuing Operating Activities	5.00	1,184	-124	103	693	575	-105	227	369	1,158	-40
Net Income / (Loss) Continuing Operations	77	467	-419	-875	-390	-275	220	283	434	481	369
Consolidated Net Income / (Loss)	77	467	-419	-875	-390	-275	220	283	434	481	369
Depreciation Expense	283	266	272	259	259	269	244	250	248	260	239
Non-Cash Adjustments To Reconcile Net Income	76	84	707	561	557	831	113	138	112	824	45
Changes in Operating Assets and Liabilities, net	-431	367	-684	158	267	-250	-682	-444	-425	-407	-693
Net Cash From Investing Activities	184	301	144	178	268	202	201	236	135	165	229
Net Cash From Continuing Investing Activities	184	301	144	178	268	202	201	236	135	165	229
Purchase of Property, Plant & Equipment	-149	-119	-124	-97	-148	-129	-127	-96	-136	-142	-168
Purchase of Investments	-38	-2.00	-12	-43	-1.00	-15	-11	-16	-13	-17	0.00
Divestitures	10	-	0.00	1.00	38	19	17	9.00	8.00	-	42
Other Investing Activities, net	361	422	295	317	339	342	322	339	276	282	355
Net Cash From Financing Activities	-576	-576	-151	-966	-	-674	-1,744	6.00	-453	40	13
Net Cash From Continuing Financing Activities	-576	-576	-151	-966	-	-674	-1,743	5.00	-453	40	13
Repayment of Debt	-1,276	-576	-9.00	-966	-	-674	-1,365	-2,300	1,852	-2,258	13
Payment of Dividends	-	-	-78	-	-	-	-340	-	-	-	0.00
Other Financing Activities, net	-	-	-64	-	-	-	-38	-	-	-	0.00
Other Net Changes in Cash	-33	68	-104	-49	100	-121	45	-5.00	-9.00	-10	-17

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	54,233	93,057	70,615	60,683	57,470	50,640	47,666	44,011	43,479	39,326	40,748
Total Current Assets	18,398	17,228	15,382	13,794	13,464	13,005	12,573	12,051	12,485	12,552	13,946
Cash & Equivalents	6,946	988	963	1,782	1,975	2,177	2,165	2,801	3,226	3,300	3,556
Accounts Receivable	5,350	7,523	7,128	5,822	5,676	4,581	4,529	3,696	3,408	3,059	3,709
Inventories, net	3,966	4,954	4,924	4,731	4,422	4,403	3,818	3,833	4,021	3,007	3,179
Prepaid Expenses	910	1,629	1,100	899	870	945	1,075	1,162	1,255	1,006	1,122
Other Current Assets	491	2,134	701	468	434	710	965	549	504	409	539
Other Current Nonoperating Assets	-	-	566	92	87	189	19	10	70	1,771	1,842
Plant, Property, & Equipment, net	6,544	8,073	7,673	6,868	6,436	6,296	5,982	5,739	5,750	4,581	4,080
Total Noncurrent Assets	29,291	67,756	47,560	40,021	37,569	31,339	29,112	26,221	25,243	22,193	22,722
Goodwill	19,025	44,409	28,414	24,917	24,846	20,624	20,040	17,633	17,177	15,147	16,000
Intangible Assets	7,675	21,487	17,640	14,005	11,232	8,923	7,466	6,270	5,387	4,418	3,781
Noncurrent Deferred & Refundable Income Taxes	250	625	574	368	386	695	596	1,458	1,812	1,799	2,191
Other Noncurrent Operating Assets	2,341	1,235	932	731	1,105	1,097	1,010	860	867	829	750
Total Liabilities & Shareholders' Equity	54,233	93,057	70,615	60,683	57,470	50,640	47,666	44,011	43,479	39,326	40,748
Total Liabilities	24,306	58,064	51,870	44,889	42,407	39,579	36,422	35,413	35,353	33,606	32,834
Total Current Liabilities	13,005	18,488	17,921	14,322	13,674	13,164	11,027	11,469	12,247	12,796	13,456
Short-Term Debt	1,585	3,276	3,646	2,216	2,345	3,188	1,426	2,109	1,672	1,781	1,820
Accounts Payable	1,918	2,157	2,069	1,853	1,718	1,756	1,686	1,887	2,602	2,203	2,531
Accrued Expenses	1,681	3,405	3,014	1,868	1,869	1,780	2,208	2,151	2,771	2,792	2,687
Current Employee Benefit Liabilities	-	-	549	870	693	685	563	566	611	624	739
Other Current Liabilities	7,821	9,534	8,605	7,515	7,048	5,757	5,144	4,755	4,579	4,698	5,325
Other Current Nonoperating Liabilities	0.00	116	38	-	-	-	-	-	13	698	354
Total Noncurrent Liabilities	11,301	39,576	33,949	30,567	28,733	26,414	25,395	23,944	23,106	20,809	19,379
Long-Term Debt	8,358	32,524	28,829	26,700	24,562	22,731	21,617	19,103	18,161	16,002	14,986
Noncurrent Deferred & Payable Income Tax Liabilities	1,748	5,413	3,277	2,140	1,096	964	784	548	606	483	296
Other Noncurrent Operating Liabilities	1,195	1,639	1,843	1,727	3,075	2,719	2,994	4,294	4,339	4,324	4,096
Commitments & Contingencies	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	29,927	34,993	18,745	15,794	15,063	11,061	11,244	8,598	8,126	5,380	7,914
Total Preferred & Common Equity	29,769	33,337	17,359	14,707	13,972	10,026	10,278	7,804	7,506	5,373	7,910
Total Common Equity	26,478	29,717	13,728	14,707	13,972	10,027	10,278	7,804	7,505	5,373	7,910
Common Stock	17,809	23,463	23,533	27,266	27,368	27,500	27,618	27,745	27,864	27,822	28,191
Retained Earnings	14,851	13,607	-3,803	-5,958	-6,956	-10,946	-10,529	-12,975	-13,534	-15,173	-13,762
Treasury Stock	-4,227	-4,194	-4,149	-4,142	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128
Accumulated Other Comprehensive Income / (Loss)	-1,955	-3,159	-1,853	-2,459	-2,312	-2,399	-2,683	-2,838	-2,697	-3,148	-2,391
Noncontrolling Interest	158	1,656	1,386	1,087	1,091	1,035	966	794	620	7.00	4.00

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	44,252	43,456	43,095	42,088	42,773	41,338	41,758	38,415	40,131	39,856	40,040
Total Current Assets	11,453	11,501	12,088	11,425	12,297	11,632	12,314	11,528	12,620	12,736	13,710
Cash & Equivalents	2,225	2,143	2,669	2,249	2,991	2,258	3,319	1,697	2,161	2,203	3,741
Accounts Receivable	3,730	3,435	3,539	3,385	3,456	3,766	3,462	3,384	3,564	3,810	3,393
Inventories, net	3,859	4,118	4,109	4,051	3,949	3,927	3,959	3,247	3,497	3,323	3,176
Prepaid Expenses	1,045	1,253	1,228	1,168	1,336	1,096	1,127	1,018	1,084	1,115	1,070
Other Current Assets	579	542	486	520	495	517	445	368	472	477	535
Other Current Nonoperating Assets	16	10	56	51	70	69	2.00	1,814	1,842	1,809	1,794
Plant, Property, & Equipment, net	5,568	5,751	5,712	5,622	5,618	5,573	5,672	4,631	4,810	4,820	3,998
Total Noncurrent Assets	27,232	26,205	25,295	25,041	24,857	24,133	23,773	22,255	22,700	22,301	22,333
Goodwill	18,433	17,799	17,118	16,885	17,007	16,488	16,124	15,477	15,949	15,945	15,822
Intangible Assets	6,393	5,964	5,738	5,525	5,056	4,853	4,756	4,189	4,142	3,936	3,609
Noncurrent Deferred & Refundable Income Taxes	1,546	1,572	1,578	1,748	1,960	2,000	2,070	1,762	1,781	1,634	2,190
Other Noncurrent Operating Assets	860	870	861	883	834	792	823	827	828	786	712
Total Liabilities & Shareholders' Equity	44,252	43,456	43,095	42,088	42,773	41,338	41,758	38,415	40,131	39,856	40,040
Total Liabilities	34,734	34,844	35,387	34,576	35,230	34,774	35,375	32,146	33,297	32,602	31,809
Total Current Liabilities	11,534	10,411	11,843	11,394	13,792	13,037	13,797	11,157	11,861	11,491	13,532
Short-Term Debt	2,769	1,023	1,980	1,479	3,060	2,094	2,580	421	464	24	2,612
Accounts Payable	1,635	2,381	2,508	2,280	2,439	2,366	2,371	2,290	2,498	2,355	2,596
Accrued Expenses	2,041	2,267	2,498	2,741	2,784	2,840	2,984	2,952	3,095	2,989	2,616
Current Employee Benefit Liabilities	496	432	451	530	492	492	619	474	481	561	555
Other Current Liabilities	4,593	4,309	4,406	4,362	4,755	4,891	5,026	4,660	4,990	5,237	4,818
Other Current Nonoperating Liabilities	-	-	-	-	262	356	216	358	334	324	334
Total Noncurrent Liabilities	23,200	24,433	23,543	23,182	21,438	21,737	21,578	20,990	21,436	21,111	18,277
Long-Term Debt	18,497	19,668	18,698	18,495	16,584	16,547	16,400	16,230	16,763	16,766	14,015
Noncurrent Deferred & Payable Income Tax Liabilities	503	550	534	544	569	553	538	461	440	399	273
Other Noncurrent Operating Liabilities	4,200	4,214	4,311	4,142	4,285	4,637	4,639	4,299	4,234	3,947	3,989
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	9,519	8,612	7,708	7,512	7,543	6,563	6,383	6,269	6,834	7,254	8,232
Total Preferred & Common Equity	8,767	7,860	7,052	6,929	7,278	6,359	6,065	6,262	6,827	7,250	8,228
Total Common Equity	8,768	7,861	7,050	6,929	7,278	6,359	6,065	6,262	6,826	7,250	8,228
Common Stock	27,709	27,776	27,805	27,837	27,854	27,887	27,918	28,023	28,061	28,096	28,262
Retained Earnings	-11,660	-13,086	-13,950	-13,870	-13,673	-14,519	-14,956	-14,958	-14,676	-14,243	-13,394
Treasury Stock	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128
Accumulated Other Comprehensive Income / (Loss)	-3,153	-2,701	-2,677	-2,910	-2,775	-2,881	-2,769	-2,675	-2,431	-2,475	-2,512
Noncontrolling Interest	751	751	656	582	265	204	319	7.00	7.00	4.00	4.00

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.06%	11.45%	-0.23%	-16.39%	-7.57%	-1.35%	-4.69%	-6.00%	6.17%	4.40%	4.32%
EBITDA Growth	-28.88%	-35.85%	-792.80%	95.36%	160.61%	-723.41%	169.78%	-193.31%	128.52%	-142.53%	1,088.89%
EBIT Growth	-35.35%	-64.97%	-2,330.46%	85.88%	51.27%	-248.30%	114.93%	-580.70%	80.27%	-105.77%	195.25%
NOPAT Growth	-26.01%	-67.65%	-1,645.18%	90.64%	72.94%	-706.32%	146.62%	-231.93%	119.71%	-169.98%	1,266.65%
Net Income Growth	-47.50%	-80.53%	-5,389.07%	84.97%	59.55%	-309.90%	111.12%	-648.03%	75.39%	-218.54%	172.38%
EPS Growth	-48.88%	-96.15%	-23,328.57%	85.55%	61.28%	-300.00%	110.44%	-678.95%	77.27%	-190.00%	183.45%
Operating Cash Flow Growth	8.09%	-29.81%	-42.80%	9.93%	-69.42%	62.57%	-34.38%	99.25%	-13.96%	-8.85%	32.24%
Free Cash Flow Firm Growth	-82.62%	-3,792.71%	121.97%	-27.74%	-54.45%	6.75%	31.57%	-3.04%	-26.25%	102.73%	-63.82%
Invested Capital Growth	4.67%	112.37%	-28.88%	-13.86%	-6.84%	-13.27%	-7.25%	-15.90%	-8.62%	-22.46%	2.85%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-4.64%	3.00%	-0.08%	-2.19%	-1.43%	3.76%	-1.36%	2.87%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	92.77%	115.62%	5.10%	-16.26%	-126.77%	146.57%	-142.86%	16.74%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	79.09%	72.58%	3.80%	-32.09%	-47.80%	73.21%	-141.81%	36.65%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	85.75%	88.20%	6.71%	-26.71%	-88.42%	133.93%	-162.99%	84.71%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	77.44%	76.84%	2.06%	-40.70%	-91.49%	74.67%	-61.10%	114.52%
EPS Q/Q Growth	0.00%	0.00%	0.00%	78.42%	76.61%	0.82%	-42.42%	-89.66%	76.19%	-72.62%	101.67%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	-16.75%	29.64%	-14.55%	18.57%	48.18%	18.24%	-32.81%	54.69%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-23.69%	-23.56%	34.51%	-5.38%	6.71%	63.31%	-40.53%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-8.21%	-1.72%	1.00%	-3.10%	-5.42%	-2.04%	-14.06%	-3.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	57.79%	53.20%	48.57%	45.41%	44.63%	46.38%	47.83%	46.72%	48.25%	48.74%	51.79%
EBITDA Margin	18.62%	10.72%	-74.44%	-4.13%	2.71%	-17.10%	12.52%	-12.43%	3.34%	-1.36%	12.89%
Operating Margin	17.06%	9.83%	-80.01%	-8.96%	-2.62%	-21.44%	10.81%	-14.72%	2.73%	-1.83%	12.50%
EBIT Margin	11.97%	3.76%	-84.10%	-14.21%	-7.49%	-26.45%	4.14%	-21.19%	-3.94%	-7.76%	7.09%
Profit (Net Income) Margin	8.13%	1.42%	-75.27%	-13.53%	-5.92%	-24.61%	2.87%	-16.74%	-3.88%	-11.84%	8.22%
Tax Burden Percent	67.90%	37.74%	89.50%	95.22%	79.05%	93.03%	69.30%	79.01%	98.56%	152.57%	115.94%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	26.96%	63.23%	0.00%	0.00%	0.00%	0.00%	32.07%	0.00%	0.00%	0.00%	-14.72%
Return on Invested Capital (ROIC)	7.61%	1.54%	-20.46%	-2.48%	-0.75%	-6.71%	3.49%	-5.20%	1.17%	-0.97%	12.75%
ROIC Less NNEP Spread (ROIC-NNEP)	-7.74%	-1.00%	-33.23%	-7.05%	-3.41%	-13.32%	0.30%	-10.10%	-4.08%	-12.63%	4.36%
Return on Net Nonoperating Assets (RNNOA)	-1.61%	-0.58%	-40.76%	-11.84%	-5.73%	-24.67%	0.59%	-19.98%	-8.53%	-27.33%	8.05%
Return on Equity (ROE)	5.99%	0.96%	-61.22%	-14.31%	-6.48%	-31.38%	4.09%	-25.19%	-7.35%	-28.30%	20.80%
Cash Return on Invested Capital (CROIC)	3.05%	-70.41%	13.29%	12.42%	6.33%	7.50%	11.02%	12.06%	10.18%	24.34%	9.94%
Operating Return on Assets (OROA)	4.67%	1.12%	-22.46%	-3.95%	-2.14%	-8.15%	1.34%	-6.90%	-1.43%	-3.10%	3.05%
Return on Assets (ROA)	3.17%	0.42%	-20.10%	-3.77%	-1.69%	-7.58%	0.93%	-5.45%	-1.41%	-4.73%	3.54%
Return on Common Equity (ROCE)	5.60%	0.83%	-49.49%	-11.78%	-6.02%	-28.83%	3.72%	-22.95%	-6.73%	-26.32%	20.27%
Return on Equity Simple (ROE_SIMPLE)	5.36%	0.93%	-94.76%	-16.81%	-7.16%	-40.88%	4.44%	-32.02%	-8.19%	-36.46%	0.00%
Net Operating Profit after Tax (NOPAT)	2,448	792	-12,239	-1,146	-310	-2,500	1,166	-1,538	303	-212	2,474
NOPAT Margin	12.46%	3.62%	-56.01%	-6.27%	-1.84%	-15.01%	7.34%	-10.30%	1.91%	-1.28%	14.34%
Net Nonoperating Expense Percent (NNEP)	15.34%	2.54%	12.78%	4.57%	2.66%	6.61%	3.20%	4.90%	5.25%	11.66%	8.39%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-5.16%	1.08%	-0.92%	10.01%
Cost of Revenue to Revenue	42.21%	46.80%	51.42%	54.59%	55.37%	53.62%	52.17%	53.28%	51.75%	51.26%	48.21%
SG&A Expenses to Revenue	6.92%	6.35%	6.64%	7.10%	7.06%	7.04%	6.92%	7.91%	7.33%	7.02%	7.46%
R&D to Revenue	7.76%	9.48%	8.14%	6.64%	5.98%	5.98%	6.09%	5.61%	6.01%	6.03%	5.87%
Operating Expenses to Revenue	40.73%	43.37%	128.58%	54.36%	47.26%	67.81%	37.03%	61.44%	45.52%	50.57%	39.29%
Earnings before Interest and Taxes (EBIT)	2,352	824	-18,379	-2,596	-1,265	-4,406	658	-3,163	-624	-1,284	1,223
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,660	2,348	-16,267	-754	457	-2,849	1,988	-1,855	529	-225	2,225
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.23	1.20	1.55	1.07	0.77	1.05	0.86	1.30	1.56	4.65	4.53
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.00	1.63	0.97	0.86	0.63	0.63	0.56	0.68	0.74	1.51	2.07
Price to Earnings (P/E)	37.54	523.92	0.00	0.00	0.00	0.00	21.19	0.00	0.00	0.00	25.39
Dividend Yield	2.21%	3.88%	4.49%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.66%	0.19%	0.00%	0.00%	0.00%	0.00%	4.72%	0.00%	0.00%	0.00%	3.94%
Enterprise Value to Invested Capital (EV/IC)	1.99	1.08	1.16	1.03	0.92	1.02	0.96	1.09	1.17	2.08	2.49
Enterprise Value to Revenue (EV/Rev)	3.33	3.46	2.65	2.40	2.17	2.12	1.93	1.97	1.83	2.41	2.84
Enterprise Value to EBITDA (EV/EBITDA)	17.89	32.25	0.00	0.00	80.36	0.00	15.43	0.00	54.69	0.00	22.05
Enterprise Value to EBIT (EV/EBIT)	27.85	91.89	0.00	0.00	0.00	0.00	46.62	0.00	0.00	0.00	40.12
Enterprise Value to NOPAT (EV/NOPAT)	26.75	95.59	0.00	0.00	0.00	0.00	26.32	0.00	95.45	0.00	19.83
Enterprise Value to Operating Cash Flow (EV/OCF)	11.82	19.46	25.98	17.96	49.10	29.07	38.45	18.45	21.15	31.92	29.75
Enterprise Value to Free Cash Flow (EV/FCFF)	66.80	0.00	7.27	7.64	14.03	12.65	8.34	8.23	11.00	7.47	25.44
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.33	1.02	1.73	1.83	1.79	2.34	2.05	2.47	2.44	3.11	2.12
Long-Term Debt to Equity	0.28	0.93	1.54	1.69	1.63	2.06	1.92	2.22	2.23	2.80	1.89
Financial Leverage	0.21	0.58	1.23	1.68	1.68	1.85	1.99	1.98	2.09	2.16	1.85
Leverage Ratio	1.89	2.27	3.05	3.80	3.83	4.14	4.41	4.62	5.23	5.98	5.87
Compound Leverage Factor	1.89	2.27	3.05	3.80	3.83	4.14	4.41	4.62	5.23	5.98	5.87
Debt to Total Capital	24.94%	50.57%	63.40%	64.67%	64.11%	70.09%	67.21%	71.16%	70.94%	75.66%	67.99%
Short-Term Debt to Total Capital	3.98%	4.63%	7.12%	4.96%	5.59%	8.62%	4.16%	7.07%	5.98%	7.58%	7.36%
Long-Term Debt to Total Capital	20.96%	45.94%	56.28%	59.72%	58.52%	61.47%	63.05%	64.08%	64.96%	68.08%	60.62%
Preferred Equity to Total Capital	8.25%	5.11%	7.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.40%	2.34%	2.71%	2.43%	2.60%	2.80%	2.82%	2.66%	2.22%	1.48%	0.02%
Common Equity to Total Capital	66.41%	41.98%	26.80%	32.89%	33.29%	27.11%	29.98%	26.18%	26.84%	22.86%	32.00%
Debt to EBITDA	2.72	15.25	-2.00	-38.35	58.88	-9.10	11.59	-11.44	37.49	-79.04	7.55
Net Debt to EBITDA	0.82	14.83	-1.94	-35.99	54.56	-8.33	10.50	-9.93	31.39	-64.37	5.96
Long-Term Debt to EBITDA	2.28	13.85	-1.77	-35.41	53.75	-7.98	10.87	-10.30	34.33	-71.12	6.74
Debt to NOPAT	4.06	45.20	-2.65	-25.23	-86.77	-10.37	19.77	-13.79	65.43	-83.84	6.79
Net Debt to NOPAT	1.22	43.95	-2.57	-23.68	-80.40	-9.50	17.91	-11.97	54.79	-68.28	5.35
Long-Term Debt to NOPAT	3.41	41.06	-2.36	-23.30	-79.21	-9.09	18.54	-12.42	59.92	-75.45	6.06
Altman Z-Score	2.47	0.82	-0.42	0.22	0.20	-0.10	0.25	-0.12	0.09	0.21	0.72
Noncontrolling Interest Sharing Ratio	6.55%	13.44%	19.15%	17.67%	7.06%	8.13%	8.97%	8.87%	8.46%	6.99%	2.57%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.41	0.93	0.86	0.96	0.98	0.99	1.14	1.05	1.02	0.98	1.04
Quick Ratio	0.95	0.46	0.45	0.53	0.56	0.51	0.61	0.57	0.54	0.50	0.54
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	980	-36,205	7,953	5,747	2,618	2,795	3,677	3,565	2,629	5,330	1,928
Operating Cash Flow to CapEx	717.88%	431.74%	254.58%	375.73%	142.48%	210.38%	141.99%	290.15%	260.08%	250.40%	329.14%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.30	0.27	0.28	0.29	0.31	0.32	0.33	0.36	0.40	0.43
Accounts Receivable Turnover	3.65	3.40	2.98	2.82	2.94	3.25	3.49	3.63	4.46	5.12	5.10
Inventory Turnover	1.99	2.30	2.28	2.07	2.04	2.02	2.02	2.08	2.09	2.41	2.69
Fixed Asset Turnover	3.01	3.00	2.78	2.51	2.54	2.62	2.59	2.55	2.76	3.20	3.99
Accounts Payable Turnover	3.26	5.03	5.32	5.09	5.24	5.14	4.81	4.45	3.65	3.53	3.52
Days Sales Outstanding (DSO)	99.91	107.26	122.35	129.35	124.26	112.37	104.71	100.57	81.82	71.34	71.57
Days Inventory Outstanding (DIO)	183.40	158.82	160.43	176.65	178.64	180.29	181.11	175.59	174.80	151.23	135.69
Days Payable Outstanding (DPO)	111.95	72.55	68.63	71.76	69.69	70.97	75.83	82.00	99.91	103.40	103.84
Cash Conversion Cycle (CCC)	171.36	193.52	214.15	234.24	233.20	221.69	209.99	194.16	156.71	119.17	103.42
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	32,924	69,921	49,729	42,836	39,908	34,613	32,102	26,999	24,673	19,131	19,677
Invested Capital Turnover	0.61	0.43	0.37	0.39	0.41	0.45	0.48	0.51	0.61	0.76	0.89
Increase / (Decrease) in Invested Capital	1,468	36,997	-20,192	-6,893	-2,928	-5,295	-2,511	-5,103	-2,326	-5,542	546
Enterprise Value (EV)	65,494	75,714	57,801	43,930	36,725	35,353	30,679	29,334	28,930	39,802	49,061
Market Capitalization	59,048	35,626	21,272	15,709	10,702	10,576	8,835	10,129	11,703	24,972	35,807
Book Value per Share	$27.68	$29.25	$12.23	$14.44	$12.79	$9.15	$9.32	$7.03	$6.70	$4.74	$6.89
Tangible Book Value per Share	($0.23)	($35.61)	($28.80)	($23.77)	($20.24)	($17.81)	($15.62)	($14.50)	($13.43)	($12.53)	($10.35)
Total Capital	39,870	70,793	51,220	44,710	41,970	36,980	34,287	29,810	27,959	23,503	24,720
Total Debt	9,943	35,800	32,475	28,916	26,907	25,919	23,043	21,212	19,833	17,783	16,806
Total Long-Term Debt	8,358	32,524	28,829	26,700	24,562	22,731	21,617	19,103	18,161	16,002	14,986
Net Debt	2,997	34,812	31,512	27,134	24,932	23,742	20,878	18,411	16,607	14,483	13,250
Capital Expenditures (CapEx)	772	901	874	651	525	578	562	548	526	498	501
Debt-free, Cash-free Net Working Capital (DFCFNWC)	32	1,028	144	-94	160	852	807	-110	-1,316	-1,763	-1,246
Debt-free Net Working Capital (DFNWC)	6,978	2,016	1,107	1,688	2,135	3,029	2,972	2,691	1,910	1,537	2,310
Net Working Capital (NWC)	5,393	-1,260	-2,539	-528	-210	-159	1,546	582	238	-244	490
Net Nonoperating Expense (NNE)	851	481	4,210	1,326	690	1,599	710	961	918	1,747	1,056
Net Nonoperating Obligations (NNO)	2,997	34,928	30,984	27,042	24,845	23,552	20,858	18,401	16,547	13,411	11,763
Total Depreciation and Amortization (D&A)	1,308	1,524	2,112	1,842	1,722	1,557	1,330	1,308	1,153	1,059	1,002
Debt-free, Cash-free Net Working Capital to Revenue	0.16%	4.69%	0.66%	-0.51%	0.95%	5.11%	5.08%	-0.74%	-8.30%	-10.66%	-7.22%
Debt-free Net Working Capital to Revenue	35.51%	9.20%	5.07%	9.24%	12.64%	18.18%	18.72%	18.03%	12.05%	9.29%	13.39%
Net Working Capital to Revenue	27.44%	-5.75%	-11.62%	-2.89%	-1.24%	-0.95%	9.74%	3.90%	1.50%	-1.47%	2.84%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.84	$0.00	($16.26)	($2.35)	($0.91)	($3.64)	$0.38	($2.12)	($0.50)	($1.45)	$1.23
Adjusted Weighted Average Basic Shares Outstanding	855M	0.00	1.02B	1.02B	1.09B	1.10B	1.10B	1.11B	1.12B	1.13B	1.15B
Adjusted Diluted Earnings per Share	$1.82	$0.00	($16.26)	($2.35)	($0.91)	($3.64)	$0.38	($2.12)	($0.50)	($1.45)	$1.21
Adjusted Weighted Average Diluted Shares Outstanding	1.02B	0.00	1.12B	1.02B	1.09B	1.10B	1.11B	1.11B	1.12B	1.13B	1.16B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.02B	0.00	1.12B	1.09B	1.09B	1.10B	1.10B	1.11B	1.12B	1.13B	1.15B
Normalized Net Operating Profit after Tax (NOPAT)	3,768	3,760	3,633	2,212	1,958	2,168	2,173	1,958	2,271	2,364	2,753
Normalized NOPAT Margin	19.18%	17.17%	16.62%	12.11%	11.59%	13.01%	13.68%	13.12%	14.33%	14.29%	15.95%
Pre Tax Income Margin	11.97%	3.76%	-84.10%	-14.21%	-7.49%	-26.45%	4.14%	-21.19%	-3.94%	-7.76%	7.09%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	72.32%	500.96%	-7.29%	-0.89%	-5.20%	0.00%	0.00%	0.00%	0.00%	-3.98%	23.98%
Augmented Payout Ratio	99.81%	500.96%	-7.29%	-0.89%	-5.20%	0.00%	0.00%	0.00%	0.00%	-3.98%	23.98%

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	1,164,426,972.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	1,164,426,972.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.32
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.09%	14.78%	4.32%	7.37%	12.52%	-5.12%	1.89%	0.29%	3.42%	11.40%	2.34%
EBITDA Growth	-28.69%	186.45%	-732.26%	102.09%	-118.39%	-97.15%	374.49%	3,384.62%	1,495.31%	1,450.00%	25.46%
EBIT Growth	-61.08%	142.20%	-71.43%	73.32%	-596.92%	-148.81%	162.82%	182.52%	299.69%	132.79%	48.30%
NOPAT Growth	174.43%	204.12%	-1,576.92%	99.24%	-108.74%	-102.92%	354.50%	18,095.07%	1,752.16%	8,811.21%	42.14%
Net Income Growth	32.76%	134.70%	-65.61%	3.53%	-606.49%	-159.10%	152.51%	132.38%	211.28%	274.28%	67.73%
EPS Growth	20.00%	135.59%	40.00%	3.85%	-750.00%	-145.24%	250.00%	132.00%	194.87%	321.05%	72.22%
Operating Cash Flow Growth	-99.08%	21.69%	14.48%	-68.21%	13,760.00%	-51.44%	15.32%	120.39%	-46.75%	101.39%	61.90%
Free Cash Flow Firm Growth	-20.44%	-31.88%	-31.76%	-34.78%	-23.22%	82.76%	91.79%	43.28%	-13.78%	-77.86%	-86.80%
Invested Capital Growth	-11.76%	-8.62%	-10.18%	-9.46%	-11.62%	-22.46%	-18.94%	-12.24%	-8.55%	2.85%	-0.55%
Revenue Q/Q Growth	-0.72%	15.77%	-14.31%	9.03%	4.03%	-2.38%	-7.99%	7.32%	7.28%	5.16%	-15.47%
EBITDA Q/Q Growth	155.95%	121.84%	-126.52%	106.63%	-592.31%	134.38%	2,345.45%	-15.80%	97.13%	-61.81%	97.95%
EBIT Q/Q Growth	107.05%	678.46%	-198.94%	47.44%	-31.30%	23.53%	219.03%	-30.95%	217.73%	-87.44%	438.27%
NOPAT Q/Q Growth	189.27%	70.13%	-123.09%	97.71%	-920.00%	43.14%	2,013.14%	62.17%	-6.35%	199.82%	-68.78%
Net Income Q/Q Growth	108.50%	506.49%	-196.77%	-108.59%	55.38%	29.23%	179.71%	28.64%	53.36%	10.83%	-23.28%
EPS Q/Q Growth	107.69%	600.00%	-131.58%	-525.00%	48.00%	51.28%	194.74%	33.33%	54.17%	13.51%	-26.19%
Operating Cash Flow Q/Q Growth	-98.46%	23,580.00%	-110.47%	183.06%	572.82%	-17.03%	-118.26%	316.19%	62.56%	213.82%	-103.45%
Free Cash Flow Firm Q/Q Growth	1.30%	-19.77%	-12.92%	-7.16%	19.25%	90.98%	-9.30%	-30.64%	-28.24%	-50.96%	-45.92%
Invested Capital Q/Q Growth	-1.84%	-2.04%	-1.11%	-4.73%	-4.18%	-14.06%	3.32%	3.15%	-0.15%	-3.35%	-0.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	48.08%	54.21%	46.37%	48.61%	49.58%	50.15%	48.24%	50.34%	51.43%	56.36%	49.52%
EBITDA Margin	9.04%	17.32%	-5.13%	0.31%	-1.48%	0.52%	13.83%	10.85%	19.93%	7.24%	16.95%
Operating Margin	8.96%	16.94%	-5.71%	-0.12%	-1.18%	-0.69%	13.34%	10.90%	19.69%	6.39%	16.37%
EBIT Margin	1.69%	11.35%	-12.25%	-5.91%	-7.46%	-5.84%	7.56%	4.86%	14.40%	1.72%	10.95%
Profit (Net Income) Margin	2.00%	10.48%	-10.97%	-20.99%	-9.00%	-6.53%	5.65%	6.78%	9.69%	10.21%	9.27%
Tax Burden Percent	118.46%	92.29%	89.72%	355.28%	120.37%	111.74%	74.83%	139.41%	67.18%	601.25%	84.44%
Interest Burden Percent	100.00%	100.00%	99.79%	100.00%	100.31%	100.00%	100.00%	100.00%	100.16%	98.77%	100.23%
Effective Tax Rate	-18.46%	7.91%	0.00%	0.00%	0.00%	0.00%	25.17%	-38.42%	33.13%	-487.50%	15.33%
Return on Invested Capital (ROIC)	6.03%	9.57%	-2.48%	-0.06%	-0.58%	-0.36%	7.51%	11.50%	10.36%	33.39%	12.20%
ROIC Less NNEP Spread (ROIC-NNEP)	4.23%	8.26%	-3.99%	-5.08%	-2.69%	-2.07%	6.40%	9.20%	9.29%	23.16%	10.73%
Return on Net Nonoperating Assets (RNNOA)	9.11%	17.26%	-8.73%	-12.34%	-6.51%	-4.48%	14.06%	20.76%	19.74%	42.76%	18.45%
Return on Equity (ROE)	15.14%	26.83%	-11.22%	-12.39%	-7.09%	-4.84%	21.58%	32.26%	30.11%	76.14%	30.65%
Cash Return on Invested Capital (CROIC)	9.17%	10.18%	11.35%	12.44%	13.76%	24.34%	22.30%	15.91%	15.22%	9.94%	13.76%
Operating Return on Assets (OROA)	0.60%	4.11%	-4.55%	-2.28%	-2.98%	-2.33%	3.09%	1.98%	5.92%	0.74%	4.84%
Return on Assets (ROA)	0.71%	3.80%	-4.07%	-8.10%	-3.60%	-2.61%	2.31%	2.77%	3.98%	4.40%	4.10%
Return on Common Equity (ROCE)	13.96%	24.56%	-10.51%	-11.64%	-6.63%	-4.50%	21.15%	31.75%	29.40%	74.18%	30.62%
Return on Equity Simple (ROE_SIMPLE)	-35.04%	0.00%	-10.73%	-11.78%	-20.05%	0.00%	-21.08%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	409	695	-153	-3.50	-36	-20	388	630	590	1,768	552
NOPAT Margin	10.62%	15.60%	-4.00%	-0.08%	-0.82%	-0.48%	9.98%	15.08%	13.17%	37.54%	13.86%
Net Nonoperating Expense Percent (NNEP)	1.81%	1.31%	1.51%	5.03%	2.11%	1.71%	1.11%	2.30%	1.08%	10.23%	1.47%
Return On Investment Capital (ROIC_SIMPLE)	-	2.49%	-	-	-	-0.09%	1.69%	2.62%	2.45%	7.15%	2.22%
Cost of Revenue to Revenue	51.92%	45.77%	53.63%	51.39%	50.39%	49.89%	51.76%	49.66%	48.57%	43.64%	50.50%
SG&A Expenses to Revenue	6.96%	6.53%	7.28%	6.80%	6.88%	7.14%	7.63%	7.30%	7.08%	7.81%	7.63%
R&D to Revenue	6.57%	5.07%	6.34%	6.46%	5.54%	5.84%	6.35%	5.84%	5.71%	5.65%	5.58%
Operating Expenses to Revenue	39.12%	37.29%	52.06%	48.75%	50.74%	50.84%	34.85%	39.44%	31.74%	49.99%	33.12%
Earnings before Interest and Taxes (EBIT)	65	506	-468	-246	-323	-247	294	203	645	81	436
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	348	772	-196	13	-64	22	538	453	893	341	675
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.65	1.56	2.17	2.89	3.37	4.65	2.78	2.82	3.20	4.53	4.21
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.75	0.74	0.99	1.13	1.22	1.51	1.05	1.16	1.38	2.07	2.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	32.55	25.39	22.13
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.07%	3.94%	4.52%
Enterprise Value to Invested Capital (EV/IC)	1.18	1.17	1.34	1.51	1.63	2.08	1.64	1.68	1.86	2.49	2.42
Enterprise Value to Revenue (EV/Rev)	1.95	1.83	2.05	2.15	2.17	2.41	1.95	2.06	2.25	2.84	2.74
Enterprise Value to EBITDA (EV/EBITDA)	0.00	54.69	108.39	37.35	69.32	0.00	63.63	36.14	19.81	22.05	20.12
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	42.19	40.12	34.81
Enterprise Value to NOPAT (EV/NOPAT)	0.00	95.45	205.11	57.00	108.09	0.00	106.61	54.80	28.19	19.83	18.25
Enterprise Value to Operating Cash Flow (EV/OCF)	25.70	21.15	23.57	29.96	19.61	31.92	25.58	24.67	35.43	29.75	27.73
Enterprise Value to Free Cash Flow (EV/FCFF)	12.07	11.00	11.20	11.50	11.15	7.47	6.58	9.88	11.65	25.44	17.52
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.66	2.44	2.60	2.84	2.97	3.11	2.66	2.52	2.31	2.12	2.02
Long-Term Debt to Equity	2.46	2.23	2.20	2.52	2.57	2.80	2.59	2.45	2.31	1.89	1.70
Financial Leverage	2.16	2.09	2.19	2.43	2.41	2.16	2.20	2.26	2.13	1.85	1.72
Leverage Ratio	5.07	5.23	5.34	5.92	6.03	5.98	5.88	6.08	5.98	5.87	5.41
Compound Leverage Factor	5.07	5.23	5.33	5.92	6.05	5.98	5.88	6.08	5.99	5.80	5.42
Debt to Total Capital	72.67%	70.94%	72.26%	73.96%	74.83%	75.66%	72.65%	71.60%	69.83%	67.99%	66.89%
Short-Term Debt to Total Capital	5.38%	5.98%	11.26%	8.31%	10.17%	7.58%	1.84%	1.93%	0.10%	7.36%	10.51%
Long-Term Debt to Total Capital	67.29%	64.96%	61.00%	65.65%	64.66%	68.08%	70.81%	69.67%	69.73%	60.62%	56.38%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.12%	2.22%	0.97%	0.81%	1.26%	1.48%	0.03%	0.03%	0.02%	0.02%	0.02%
Common Equity to Total Capital	25.21%	26.84%	26.77%	25.23%	23.91%	22.86%	27.32%	28.37%	30.15%	32.00%	33.10%
Debt to EBITDA	-17.58	37.49	65.05	19.89	36.15	-79.04	32.71	18.15	8.81	7.55	7.04
Net Debt to EBITDA	-15.60	31.39	55.14	17.48	29.83	-64.37	29.38	15.88	7.65	5.96	5.46
Long-Term Debt to EBITDA	-16.28	34.33	54.91	17.66	31.24	-71.12	31.89	17.66	8.80	6.74	5.93
Debt to NOPAT	-22.36	65.43	123.08	30.36	56.37	-83.84	54.81	27.53	12.53	6.79	6.39
Net Debt to NOPAT	-19.84	54.79	104.34	26.69	46.51	-68.28	49.22	24.07	10.89	5.35	4.95
Long-Term Debt to NOPAT	-20.71	59.92	103.91	26.95	48.71	-75.45	53.42	26.79	12.52	6.06	5.38
Altman Z-Score	0.11	0.17	0.12	0.16	0.18	0.30	0.25	0.29	0.44	0.63	0.66
Noncontrolling Interest Sharing Ratio	7.83%	8.46%	6.29%	6.04%	6.48%	6.99%	1.97%	1.58%	2.36%	2.57%	0.08%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.00	1.02	0.89	0.89	0.89	0.98	1.03	1.06	1.11	1.04	1.01
Quick Ratio	0.49	0.54	0.47	0.46	0.49	0.50	0.46	0.48	0.52	0.54	0.53
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	3,766	3,021	2,611	2,425	2,891	5,522	5,008	3,474	2,493	1,222	661
Operating Cash Flow to CapEx	3.36%	994.96%	-100.00%	106.19%	468.24%	445.74%	-82.68%	236.46%	271.32%	815.49%	-23.81%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.36	0.37	0.39	0.40	0.40	0.41	0.41	0.41	0.43	0.44
Accounts Receivable Turnover	4.29	4.46	4.64	4.46	4.90	5.12	4.86	4.54	4.61	5.10	5.12
Inventory Turnover	2.09	2.09	2.03	2.05	2.10	2.41	2.35	2.26	2.30	2.69	2.59
Fixed Asset Turnover	2.73	2.76	2.82	2.89	2.97	3.20	3.24	3.20	3.20	3.99	4.02
Accounts Payable Turnover	4.23	3.65	3.39	3.38	3.62	3.53	3.57	3.45	3.54	3.52	3.40
Days Sales Outstanding (DSO)	85.02	81.82	78.58	81.84	74.50	71.34	75.13	80.45	79.11	71.57	71.29
Days Inventory Outstanding (DIO)	174.49	174.80	180.22	178.26	173.80	151.23	155.47	161.66	158.70	135.69	140.94
Days Payable Outstanding (DPO)	86.36	99.91	107.68	108.12	100.92	103.40	102.17	105.92	103.00	103.84	107.21
Cash Conversion Cycle (CCC)	173.15	156.71	151.12	151.98	147.39	119.17	128.43	136.20	134.81	103.42	105.02
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	25,188	24,673	24,387	23,233	22,261	19,131	19,767	20,389	20,358	19,677	19,658
Invested Capital Turnover	0.57	0.61	0.62	0.67	0.71	0.76	0.75	0.76	0.79	0.89	0.88
Increase / (Decrease) in Invested Capital	-3,357	-2,326	-2,764	-2,428	-2,927	-5,542	-4,620	-2,844	-1,903	546	-109
Enterprise Value (EV)	29,738	28,930	32,735	34,992	36,395	39,802	32,388	34,296	37,763	49,061	47,522
Market Capitalization	11,431	11,703	15,817	18,405	20,415	24,972	17,427	19,223	23,172	35,807	34,632
Book Value per Share	$6.18	$6.70	$6.48	$5.61	$5.35	$4.74	$5.52	$5.95	$6.32	$6.89	$7.16
Tangible Book Value per Share	($13.81)	($13.43)	($13.17)	($13.23)	($13.08)	($12.53)	($11.82)	($11.57)	($11.01)	($10.35)	($9.74)
Total Capital	27,486	27,959	27,187	25,204	25,363	23,503	22,920	24,061	24,044	24,720	24,859
Total Debt	19,974	19,833	19,644	18,641	18,980	17,783	16,651	17,227	16,790	16,806	16,627
Total Long-Term Debt	18,495	18,161	16,584	16,547	16,400	16,002	16,230	16,763	16,766	14,986	14,015
Net Debt	17,725	16,607	16,653	16,383	15,661	14,483	14,954	15,066	14,587	13,250	12,886
Capital Expenditures (CapEx)	149	119	124	97	148	129	127	96	136	142	168
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-739	-1,316	-1,426	-1,569	-2,222	-1,763	-905	-938	-934	-1,246	-951
Debt-free Net Working Capital (DFNWC)	1,510	1,910	1,565	689	1,097	1,537	792	1,223	1,269	2,310	2,790
Net Working Capital (NWC)	31	238	-1,495	-1,405	-1,483	-244	371	759	1,245	490	178
Net Nonoperating Expense (NNE)	332	228	266	871	354	256	168	347	156	1,287	183
Net Nonoperating Obligations (NNO)	17,676	16,547	16,844	16,670	15,878	13,411	13,498	13,555	13,104	11,763	11,426
Total Depreciation and Amortization (D&A)	283	266	272	259	259	269	244	250	248	260	239
Debt-free, Cash-free Net Working Capital to Revenue	-4.84%	-8.30%	-8.91%	-9.63%	-13.25%	-10.66%	-5.45%	-5.64%	-5.57%	-7.22%	-5.48%
Debt-free Net Working Capital to Revenue	9.89%	12.05%	9.78%	4.23%	6.54%	9.29%	4.77%	7.36%	7.56%	13.39%	16.08%
Net Working Capital to Revenue	0.20%	1.50%	-9.34%	-8.62%	-8.84%	-1.47%	2.23%	4.56%	7.42%	2.84%	1.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.07	$0.42	($0.12)	($0.75)	($0.39)	($0.19)	$0.19	$0.25	$0.38	$0.41	$0.32
Adjusted Weighted Average Basic Shares Outstanding	1.12B	1.12B	1.12B	1.13B	1.13B	1.13B	1.14B	1.15B	1.15B	1.15B	1.16B
Adjusted Diluted Earnings per Share	$0.07	$0.42	($0.12)	($0.75)	($0.39)	($0.19)	$0.18	$0.24	$0.37	$0.42	$0.31
Adjusted Weighted Average Diluted Shares Outstanding	1.14B	1.12B	1.12B	1.13B	1.13B	1.13B	1.16B	1.16B	1.16B	1.16B	1.18B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.12B	1.12B	1.13B	1.13B	1.13B	1.13B	1.15B	1.15B	1.15B	1.15B	1.16B
Normalized Net Operating Profit after Tax (NOPAT)	534	731	449	573	703	639	527	627	714	886	642
Normalized NOPAT Margin	13.87%	16.41%	11.75%	13.77%	16.22%	15.11%	13.54%	15.00%	15.94%	18.81%	16.12%
Pre Tax Income Margin	1.69%	11.35%	-12.23%	-5.91%	-7.48%	-5.84%	7.56%	4.86%	14.42%	1.70%	10.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-3.98%	-25.76%	-208.59%	51.44%	23.98%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-3.98%	-25.76%	-208.59%	51.44%	23.98%	0.00%

Financials Breakdown Chart

Key Financial Trends

Teva Pharmaceutical Industries (TEVA) — four-year trend snapshot

Q4 2025 revenue strength: Operating revenue reached 4.711B, up from 4.488B in Q3 2025 and 3.891B in Q1 2025, signaling an upturn into year-end.
Gross profit expansion: Q4 2025 gross profit was 2.655B, higher than 2.304B (Q3 2025) and 2.121B (Q4 2024), indicating improved product profitability.
Net income and earnings per share improving: Q4 2025 net income attributable to common shareholders was 481M with diluted EPS of 0.42, up from prior-year quarters.
Strong cash generation from operations: Q4 2025 net cash from continuing operating activities was 1.158B, and net cash from operating activities was also 1.158B, underscoring healthy cash flow generation.
Net cash from investing activities turned positive in Q4 2025: +165M, aided by a 42M sale of investments and other inflows, suggesting some optionality for capital management despite ongoing capex needs.
Liquidity position appears solid but modestly leveraged: For Q3 2025, total current assets were about 12.736B and total current liabilities about 11.491B, yielding a modest working-capital cushion and a current ratio near 1.1.
Debt load remains sizable: Long-term debt around 16.7B and total liabilities near 32.6B on the Q3 2025 balance sheet, with total equity around 7.3B, indicating ongoing leverage but a relatively stable capital structure.
Significant one-time costs in Q4 2025: Restructuring charge of 778M and impairment charge of 32M weighed on operating profitability in the quarter.
Near-term operating expense pressures: Q4 2025 Total Operating Expenses of about 2.355B eclipsed gross profit of 2.655B, leading to lower quarterly operating income (0.301B vs. higher earlier quarter profitability).
Tax impact favorable in some quarters: Q4 2025 shows a negative income tax expense (tax benefit) of about 390M, boosting net income in that period.

05/11/26 02:54 PM ETAI Generated. May Contain Errors.

Teva Pharmaceutical Industries Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Teva Pharmaceutical Industries' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Teva Pharmaceutical Industries' net income appears to be on a downward trend, with a most recent value of $1.42 billion in 2025, falling from $1.60 billion in 2015. The previous period was -$1.96 billion in 2024. See Teva Pharmaceutical Industries' forecast for analyst expectations on what's next for the company.

Teva Pharmaceutical Industries' total operating income in 2025 was $2.16 billion, based on the following breakdown:

Total Gross Profit: $8.94 billion
Total Operating Expenses: $6.78 billion

Over the last 10 years, Teva Pharmaceutical Industries' total revenue changed from $19.65 billion in 2015 to $17.26 billion in 2025, a change of -12.2%.

Teva Pharmaceutical Industries' total liabilities were at $32.83 billion at the end of 2025, a 2.3% decrease from 2024, and a 35.1% increase since 2015.

In the past 10 years, Teva Pharmaceutical Industries' cash and equivalents has ranged from $963 million in 2017 to $6.95 billion in 2015, and is currently $3.56 billion as of their latest financial filing in 2025.

Over the last 10 years, Teva Pharmaceutical Industries' book value per share changed from 27.68 in 2015 to 6.89 in 2025, a change of -75.1%.

Related Companies

Financial statements for NYSE:TEVA last updated on 5/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Teva Pharmaceutical Industries (TEVA) Financials

Financials Breakdown Chart

Key Financial Trends

Teva Pharmaceutical Industries Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Teva Pharmaceutical Industries (TEVA) Financials

Annual Income Statements for Teva Pharmaceutical Industries

Quarterly Income Statements for Teva Pharmaceutical Industries

Annual Cash Flow Statements for Teva Pharmaceutical Industries

Quarterly Cash Flow Statements for Teva Pharmaceutical Industries

Annual Balance Sheets for Teva Pharmaceutical Industries

Quarterly Balance Sheets for Teva Pharmaceutical Industries

Annual Metrics And Ratios for Teva Pharmaceutical Industries

Quarterly Metrics And Ratios for Teva Pharmaceutical Industries

Financials Breakdown Chart

Key Financial Trends

Teva Pharmaceutical Industries Financials - Frequently Asked Questions

When does Teva Pharmaceutical Industries' financial year end?

How has Teva Pharmaceutical Industries' net income changed over the last 10 years?

What is Teva Pharmaceutical Industries' operating income?

How has Teva Pharmaceutical Industries' revenue changed over the last 10 years?

How much debt does Teva Pharmaceutical Industries have?

How much cash does Teva Pharmaceutical Industries have?

How has Teva Pharmaceutical Industries' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools